US Patent No: 7,875,677

Number of patents in Portfolio can not be more than 2000

Micellar drug delivery systems for hydrophobic drugs

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This invention provides compositions comprising a hydrophobic drug, a biocompatible micelle forming polymer, and a biocompatible low molecular weight, water-soluble polymer. Also provided are devices for injection of such compositions and for the use of such compositions to form hydrophobic drug containing micelles within the body of a patient.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
THE UNIVERSITY OF BRITISH COLUMBIAVANCOUVER314

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Burt, Helen M Vancouver, CA 28 364
Jackson, John K Vancouver, CA 36 518
Zastre, Jason Vancouver, CA 3 9

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (1)
5,843,891 Pharmaceutical acceptable compositions containing an alcohol and a hydrophobic drug 35 1995
 
PROTHERICS SALT LAKE CITY, INC. (1)
6,592,899 PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water 25 2001
 
Gerhard Gergely (1)
5,834,019 Pharmaceutical formulation containing a hydrophobic active substance and an effervescent system 7 1996
 
KIM PH.D., SUNG WAN (2)
6,004,573 Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties 208 1997
6,117,949 Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties 81 1998
 
CEPHALON LIMITED (1)
6,107,332 Hydrolysis-promoting hydrophobic taxane derivatives 3 1999
 
ANGIOTECH PHARMACEUTICALS, INC. (4)
5,886,026 Anti-angiogenic compositions and methods of use 259 1995
5,994,341 Anti-angiogenic Compositions and methods for the treatment of arthritis 79 1995
6,506,411 Anti-angiogenic compositions and methods of use 89 1999
6,544,544 Anti-angiogenic compositions and methods of use 168 2001
 
APHIOS CORPORATION (1)
5,776,486 Methods and apparatus for making liposomes containing hydrophobic drugs 39 1996
 
IPXMEDICAL, LLC (3)
6,515,016 Composition and methods of paclitaxel for treating psoriasis 40 1997
6,495,579 Method for treating multiple sclerosis 17 1998
6,689,803 Compositions and methods for treating surgical adhesions 88 2002
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (1)
5,955,509 pH dependent polymer micelles 213 1997
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (1)
4,942,184 Water soluble, antineoplastic derivatives of taxol 162 1988
 
The Scripps Research Institute (2)
5,274,137 Intermediates for preparation of taxols 34 1992
5,422,364 Water soluble taxol derivatives 52 1993
 
ANGIOTECH BIOCOATINGS CORP. (1)
5,716,981 Anti-angiogenic compositions and methods of use 795 1995
 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (1)
5,543,158 Biodegradable injectable nanoparticles 362 1993
 
BAKER NORTON PHARMACEUTICALS, INC. (1)
5,968,972 Method for increasing the oral bioactivity of pharmaceutical agents 29 1996
 
Rhone-Poulenc S.A. (1)
5,453,521 Process for obtaining 10-deacetylbaccatin III 13 1993
 
Rhone-Poulenc Sante (1)
4,857,653 Process for the preparation of taxol and 10-deacetyltaxol 180 1987
 
VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY (4)
5,059,699 Water soluble derivatives of taxol 118 1990
5,352,805 Water soluble derivatives of taxol 18 1991
5,278,324 Water soluble derivatives of taxol 58 1991
5,411,984 Water soluble analogs and prodrugs of taxol 20 1992
 
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (1)
5,200,534 Process for the preparation of taxol and 10-deacetyltaxol 66 1992
 
Supernus Pharmaceuticals, Inc. (1)
5,430,021 Hydrophobic drug delivery systems 53 1994
 
BRISTOL-MYERS SQUIBB COMPANY (8)
5,248,796 Taxol derivatives 79 1992
5,300,638 Asymmetric synthesis of taxol side chain 32 1992
5,272,171 Phosphonooxy and carbonate derivatives of taxol 101 1992
5,254,580 7,8-cyclopropataxanes 121 1993
5,294,637 Fluoro taxols 72 1993
5,380,751 6,7-modified paclitaxels 38 1993
5,412,092 N-substituted 2-azetidinones 45 1993
5,395,850 6,7-epoxy paclitaxels 23 1994
 
E. I. DU PONT DE NEMOURS AND COMPANY (1)
4,650,913 Sulfinate-initiated addition of perfluorinated iodides to olefins 12 1984
 
Cornell Research Foundation, Inc. (1)
6,369,037 Controlled release of doxorubicin 2 2000
 
RESEARCH DEVELOPMENT CORPORATION OF JAPAN (1)
5,510,103 Physical trapping type polymeric micelle drug preparation 54 1995
 
Supratek Pharma Inc. (1)
6,153,193 Compositions for targeting biological agents 12 1995
 
TEKMIRA PHARMACEUTICALS CORPORATION (1)
5,478,860 Stable microemulsions for hydrophobic compound delivery 56 1993
 
MAYNE PHARMA (USA), INC. (1)
5,202,448 Processes of converting taxanes into baccatin III 36 1992
 
EFRAT BIOPOLYMERS LTD. (1)
6,365,173 Stereocomplex polymeric carriers for drug delivery 49 1999
 
UNIVERSITY OF DELAWARE (1)
4,419,340 Controlled release of anticancer agents from biodegradable polymers 51 1980
 
SYNGENTA LIMITED (1)
4,745,160 Biodegradable amphipathic copolymers 145 1985
 
DUKE UNIVERSITY (1)
5,827,533 Liposomes containing active agents aggregated with lipid surfactants 39 1997
 
VESTAR, INC. (1)
5,484,809 Prodrugs for oral administration containing taxol or substituted taxol covalently bound to a phospholipid 50 1994
 
SUPERGEN, INC. (2)
6,017,948 Water-miscible pharmaceutical compositions 20 1998
6,136,846 Formulation for paclitaxel 51 1999
 
SUCAMPO AG (1)
5,229,529 Method of producing .alpha.,.beta.-unsaturated ketolactones 26 1992
 
AVENTIS PHARMA S.A. (6)
4,814,470 Taxol derivatives, their preparation and pharmaceutical compositions containing them 259 1987
5,393,895 Process for obtaining 10-deacetylbaccatin III 8 1993
5,393,896 Process for obtaining 10-deacetylbaccatin III 7 1993
5,717,103 Process for the esterification of baccatin III and of 10-deacetylbaccatin III 4 1995
5,736,366 Process for obtaining 10-deacetylbaccatin III 6 1995
5,977,375 Esters of baccatin III and 10-deacetylbaccatin III 1 1997
 
BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (1)
5,279,949 Process for the isolation and purification of taxol and taxanes from Taxus spp 42 1992
 
ABRAXIS BIOSCIENCE, LLC (1)
5,916,596 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof 166 1996
 
PHARMACIA & UPJOHN S.P.A. (1)
5,362,831 Polymer-bound paclitaxel derivatives 111 1993
 
ABBOTT LABORATORIES (1)
5,440,056 9-deoxotaxane compounds 48 1994
 
SAMYANG BIOPHARMACEUTICALS CORPORATION (3)
6,210,717 Biodegradable mixed polymeric micelles for gene delivery 31 1998
6,322,805 Biodegradable polymeric micelle-type drug composition and method for the preparation thereof 47 2000
6,616,941 Polymeric composition for solubilizing poorly water soluble drugs and process for the preparation thereof 18 2001
 
BOSTON SCIENTIFIC SCIMED, INC. (5)
5,811,447 Therapeutic inhibitor of vascular smooth muscle cells 216 1995
5,981,568 Therapeutic inhibitor of vascular smooth muscle cells 328 1997
6,306,421 Therapeutic inhibitor of vascular smooth muscle cells 103 1997
6,231,600 Stents with hybrid coating for medical devices 406 1999
6,358,989 Therapeutic inhibitor of vascular smooth muscle cells 54 1999
 
R.P. SCHERER CORPORATION (2)
5,645,856 Delivery systems for hydrophobic drugs 135 1995
5,827,541 Process for preparing solid pharmaceutical dosage forms of hydrophobic substances 27 1996
 
BIONUMERIK PHARMACEUTICALS, INC. (1)
6,040,330 Pharmaceutical formulations of taxanes 21 1999
 
BASF AKTIENGESELLSCHAFT (1)
5,939,454 Fungicidal mixtures of an oxime ether carboxylic acit amide with a dithiocarbamate 1 1998
 
IMPERIAL CHEMICAL INDUSTRIES PLC (1)
4,526,938 Continuous release formulations 294 1983
 
THE FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (2)
5,350,866 10-desacetoxytaxol derivatives 73 1992
5,283,253 Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them 97 1992
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
WISCONSIN ALUMNI RESEARCH FOUNDATION (1)
8,858,965 Micelle encapsulation of a combination of therapeutic agents 0 2013
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (2)
* 9,283,185 Liposomal curcumin for treatment of cancer 0 2011
* 2011/0287,085 LIPOSOMAL CURCUMIN FOR TREATMENT OF CANCER 4 2011
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 25, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 25, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00